While CX-4945 enhances chemotherapy in other solid malignancies49,50, our findings indicate that in NSCLC, a strategy to first select tumours based on CDCA3 expression would enhance CX-4945 potency and sensitivity to platinum agents. The gene discussed is CDCA3; the disease is non-small cell lung carcinoma.